Aegle Therapeutics is developing a series of novel therapeutics based on our proprietary extracellular vesicle isolation technology. The ability to properly isolate EVs from MSCs is critical to the success of extracellular vesicle therapy.
By their nature, bone marrow-MSC derived EVs do not trigger an immune response in the body. However, commonly used isolation processes can cause structural or functional damage to the EVs. Our preclinical research has shown that EVs isolated using traditional methods trigger an immune response in porcine wound models, resulting in inflammation and lack of healing. In the same model, EVs isolated with our proprietary methodology accelerate healing, minimize/eliminate scarring and promote blood vessel and nerve regeneration as well as hair follicle growth.
Aegle’s isolation process allows for the production of therapeutic-grade extracellular vesicles from bone marrow derived MSCs. Our proprietary process is scalable and low cost.